AG
CTMX icon

Aperio Group’s CytomX Therapeutics CTMX Stock Holding History

Aperio Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$110K Sell
16,834
-3,001
-15% -$21.4K ﹤0.01% 2374
2020
Q3 		$132K Buy
19,835
+629
+3% +$4.67K ﹤0.01% 2292
2020
Q2 		$160K Buy
19,206
+8,439
+78% +$78.4K ﹤0.01% 2217
2020
Q1 		$83K Buy
+10,767
New +$75.1K ﹤0.01% 2233
2019
Q4 		– Sell
-10,678
Closed -$79K – 2329
2019
Q3 		$79K Buy
10,678
+4,406
+70% +$43.5K ﹤0.01% 2256
2019
Q2 		$70K Buy
+6,272
New +$65.8K ﹤0.01% 2476

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aperio Group's CTMX Position: Q4 2020 in Review

Aperio Group reduced its CytomX Therapeutics (CTMX) stake by 15% in Q4 2020, selling an estimated $21.4K and leaving 16,834 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

Aperio Group first reported a position in CTMX in Q2 2019 and has held it in 6 quarters since. The position peaked at $160K in Q2 2020. 126 funds tracked by Wall St. Rank hold CTMX as of Q4 2020.

  • Aperio Group held 16,834 shares of CytomX Therapeutics worth $110K as of Q4 2020.
  • Aperio Group sold 3,001 CytomX Therapeutics shares in Q4 2020, an estimated $21.4K.
  • CytomX Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2374 holding.
  • Aperio Group first reported a position in CytomX Therapeutics in Q2 2019 and has held it in 6 quarters since.
  • Aperio Group's CytomX Therapeutics position peaked at $160K in Q2 2020.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.